Healthcare DIVE November 6, 2024
Still, gross spending on the drugs increased by more than 500% from 2019 to 2023, according to the health policy research firm.
Dive Brief:
- Few Medicaid programs cover GLP-1 drugs for obesity as states grapple with the medications’ high cost, according to an analysis by KFF.
- Thirteen programs for the safety-net coverage include the newer glucagon-like peptide-1 drugs for weight loss as of August 2024, the health policy research firm found.
- Still, GLP-1 prescriptions and spending in Medicaid are increasing quickly. From 2019 to 2023, the number of prescriptions spiked by more than 400%, while gross spending soared by more than 500%.
Dive Insight:
GLP-1s currently make up a small portion of Medicaid prescriptions and spending...
Today's Sponsors
Today's Sponsor
Topics: Biotechnology, Govt Agencies, Insurance, Medicaid, Pharma / Biotech, States, Survey / Study, Trends